Skip to search formSkip to main contentSkip to account menu

RoActemra®

Known as: RoActemra 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
TNFAIP3 encodes the NF-κB regulatory protein A20. High-penetrance heterozygous mutations in TNFAIP3 cause a haploinsufficiency of… 
2018
2018
ABSTRACT K-Ras mutations are a hallmark of human pancreatic adenocarcinoma (PDAC) and epithelial-mesenchymal-transition (EMT) is… 
Review
2017
Review
2017
Intravenous (IV) and subcutaneous (SC) tocilizumab (RoActemra®), an IL-6 receptor antagonist, are approved (± methotrexate) in… 
Review
2016
Review
2016
BACKGROUND Juvenile idiopathic arthritis (JIA) is characterised by joint pain, swelling and a limitation of movement caused by… 
Review
2013
Review
2013
Rheumatoid arthritis (RA) is an autoimmune chronic disease which is associated with an increasing disability in patients and high… 
Review
2013
Review
2013
Tocilizumab (Actemra®, RoActemra®) is a humanized monoclonal antibody that acts as an interleukin-6 receptor antagonist… 
Highly Cited
2012
Highly Cited
2012
To the Editor: Anti-interleukin 6 receptor (anti-IL-6R) antibodies have been effective in experimental models of autoimmune… 
Review
2011
Review
2011
  • R. Alten
  • Therapeutic Advances in Musculoskeletal Disease
  • 2011
  • Corpus ID: 8591212
Tocilizumab (TCZ; RoActemra® or Actemra®) is a recombinant humanized monoclonal antibody that acts as an interleukin 6 (IL-6… 
Review
2009
Review
2009
Tocilizumab (RoActemra or Actemra) is a recombinant humanized monoclonal antibody that acts as an interleukin (IL)-6 receptor… 
Review
2009
Review
2009
▼Tocilizumab (RoActemra – Roche) is a new biological agent available in the UK for the treatment of adults with rheumatoid…